Update on aspirin in the treatment and prevention of cardiovascular disease

American Journal of Managed Care

Volumn 8, Issue 22 SUPPL., 2002, Pages

  Hennekens, Charles H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DAZOXIBEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; FELODIPINE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FLURBIPROFEN; IBUPROFEN; PICOTAMIDE; PLACEBO; STREPTOKINASE; SULFINPYRAZONE; SULOCTIDIL; SULOTROBAN; TICLOPIDINE; TRAPIDIL; TRIFLUSAL; VAPIPROST; WARFARIN;

ACUTE HEART INFARCTION; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DEATH; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG USE; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE ORGANIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS; MORTALITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SIDE EFFECT; STABLE ANGINA PECTORIS; STATISTICAL SIGNIFICANCE; STROKE; SURVIVAL; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

EID: 0036927418     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation. 1997;96:2751-2753.
2. Murray CJL, Lopez AD. The Global Burden of Disease. Cambridge, Mass: Harvard University Press; 1996.
3. Cook NR, Hebert PR, Manson JE, Buring JE, Hennekens CH. Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the Physicians' Health Study. Arch Intern Med. 2000;160:921-928.
4. American Stroke Association/American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2001.
5. American Cancer Society. Cancer Facts and Figures - 1999. Atlanta, Ga: American Cancer Society; 1999. Publication No. 99-300M-No. 5008.99.
6. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235.
7. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular events by prolonged antiplatelet therapy. BMJ. 1998;296:320-331.
8. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
10. UK-TIA Study Group. United Kingdom Transient Ischemic Attack (UK-TIA) aspirin trial: Interim results. BMJ. 1988;296:316-320.
11. Hennekens CH, Jonas MA, Buring JE. The benefits of aspirin in acute myocardial infarction. Arch Intern Med. 1994;154:37-39.
12. Aspirin Foundation of America. Professional section. Heart attacks. Available at http://www.aspirin.org/prof01.html. Accessed September 23, 2002.
13. Eidelman RS, Hebert P, Weisman S, Hennekens CH. Update on aspirin in the primary prevention of CVD. Arch Intern Med. In press.
14. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
15. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997;349:1641-1649.
16. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet. 1997;349(9065):1569-1581.
17. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
18. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313-316.
19. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet. 1998;351:233-241.
20. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
21. De Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Lancet. 2001;357:89-95.
22. Hennekens CH, Peto R, Hutchison GB, Doll R. An overview of the British and American aspirin studies. N Engl J Med. 1988;318:923-924.
23. Hebert PR, Hennekens CH. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease. Arch Intern Med. 2000;160:3123-3127.
24. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med. 2002;136:157-160.
25. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation. 2002;106:388-391.